新一代宏基因组测序在腹膜透析相关性腹膜炎早期诊断中的临床价值:一项随机对照观察试验。

IF 1.9
Aiting Li, Zhijin Chen, Qianyun Deng, Caiyan Zheng, Haofei Hu, Zhiming Ye
{"title":"新一代宏基因组测序在腹膜透析相关性腹膜炎早期诊断中的临床价值:一项随机对照观察试验。","authors":"Aiting Li, Zhijin Chen, Qianyun Deng, Caiyan Zheng, Haofei Hu, Zhiming Ye","doi":"10.1111/nep.70094","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>While metagenomic next-generation sequencing (mNGS) is a high-throughput diagnostic tool capable of rapidly and accurately identifying pathogenic microorganisms, predicting their antibiotic resistance/susceptibility profiles, its clinical utility in peritoneal dialysis-associated peritonitis (PDAP) remains unvalidated. This study aims to evaluate its ability to enable early pathogen detection and predict antibiotic susceptibility, thereby informing optimised treatment strategies.</p><p><strong>Method: </strong>A prospective randomised controlled trial was conducted in patients diagnosed with PDAP. Participants were divided into two groups: (1) the culture & mNGS group (n = 78), where both conventional dialysis effluent culture and mNGS were performed, and clinicians had access to mNGS results; and (2) the only culture group (n = 76), where clinicians relied solely on culture results. All patients were examined for mNGS, but only patients in the culture & mNGS group had mNGS results that were known to their clinicians. Empirical intraperitoneal antimicrobial therapy was initiated for all patients, with subsequent regimen adjustments based on clinical judgement, culture reports, and/or mNGS findings. The study duration spanned from the initiation of anti-infective therapy to 3 months post-treatment. Outcomes included the comparative performance of culture versus mNGS, mNGS-based antimicrobial resistance prediction accuracy, and the clinical impact on treatment decisions.</p><p><strong>Results: </strong>The culture & mNGS group demonstrated a significantly higher pathogen detection rate than the only culture group (p = 0.001). mNGS identified pathogens faster than conventional culture (p < 0.001) and detected polymicrobial infections at a higher rate (p = 0.018). mNGS achieved 88.94% accuracy in predicting antimicrobial resistance. No significant difference was observed between the culture & mNGS group and the only culture group in time to normalisation of dialysis effluent leukocyte counts (p = 0.31).</p><p><strong>Conclusion: </strong>Integrating mNGS into diagnostic workflows enhances pathogen detection efficiency, accelerates results, and improves the precision of antimicrobial therapy. These advantages suggest that mNGS-guided strategies may optimise clinical management of PDAP.</p><p><strong>Trial registration: </strong>ChiClinicalTrials.gov identifier: CTR2300070995 (28/04/2023).</p>","PeriodicalId":520716,"journal":{"name":"Nephrology (Carlton, Vic.)","volume":"30 8","pages":"e70094"},"PeriodicalIF":1.9000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12319393/pdf/","citationCount":"0","resultStr":"{\"title\":\"Clinical Value of Metagenomic Next-Generation Sequencing in Early Diagnosis of Peritoneal Dialysis-Associated Peritonitis: A Randomised Controlled Observational Trial.\",\"authors\":\"Aiting Li, Zhijin Chen, Qianyun Deng, Caiyan Zheng, Haofei Hu, Zhiming Ye\",\"doi\":\"10.1111/nep.70094\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aim: </strong>While metagenomic next-generation sequencing (mNGS) is a high-throughput diagnostic tool capable of rapidly and accurately identifying pathogenic microorganisms, predicting their antibiotic resistance/susceptibility profiles, its clinical utility in peritoneal dialysis-associated peritonitis (PDAP) remains unvalidated. This study aims to evaluate its ability to enable early pathogen detection and predict antibiotic susceptibility, thereby informing optimised treatment strategies.</p><p><strong>Method: </strong>A prospective randomised controlled trial was conducted in patients diagnosed with PDAP. Participants were divided into two groups: (1) the culture & mNGS group (n = 78), where both conventional dialysis effluent culture and mNGS were performed, and clinicians had access to mNGS results; and (2) the only culture group (n = 76), where clinicians relied solely on culture results. All patients were examined for mNGS, but only patients in the culture & mNGS group had mNGS results that were known to their clinicians. Empirical intraperitoneal antimicrobial therapy was initiated for all patients, with subsequent regimen adjustments based on clinical judgement, culture reports, and/or mNGS findings. The study duration spanned from the initiation of anti-infective therapy to 3 months post-treatment. Outcomes included the comparative performance of culture versus mNGS, mNGS-based antimicrobial resistance prediction accuracy, and the clinical impact on treatment decisions.</p><p><strong>Results: </strong>The culture & mNGS group demonstrated a significantly higher pathogen detection rate than the only culture group (p = 0.001). mNGS identified pathogens faster than conventional culture (p < 0.001) and detected polymicrobial infections at a higher rate (p = 0.018). mNGS achieved 88.94% accuracy in predicting antimicrobial resistance. No significant difference was observed between the culture & mNGS group and the only culture group in time to normalisation of dialysis effluent leukocyte counts (p = 0.31).</p><p><strong>Conclusion: </strong>Integrating mNGS into diagnostic workflows enhances pathogen detection efficiency, accelerates results, and improves the precision of antimicrobial therapy. These advantages suggest that mNGS-guided strategies may optimise clinical management of PDAP.</p><p><strong>Trial registration: </strong>ChiClinicalTrials.gov identifier: CTR2300070995 (28/04/2023).</p>\",\"PeriodicalId\":520716,\"journal\":{\"name\":\"Nephrology (Carlton, Vic.)\",\"volume\":\"30 8\",\"pages\":\"e70094\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2025-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12319393/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nephrology (Carlton, Vic.)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1111/nep.70094\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nephrology (Carlton, Vic.)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1111/nep.70094","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

目的:虽然新一代宏基因组测序(mNGS)是一种高通量诊断工具,能够快速准确地识别病原微生物,预测其抗生素耐药性/敏感性,但其在腹膜透析相关性腹膜炎(PDAP)中的临床应用仍未得到验证。本研究旨在评估其早期病原体检测和预测抗生素敏感性的能力,从而为优化治疗策略提供信息。方法:对诊断为PDAP的患者进行前瞻性随机对照试验。参与者被分为两组:(1)培养和mNGS组(n = 78),其中进行常规透析废水培养和mNGS,临床医生可以获得mNGS结果;(2)唯一的培养组(n = 76),临床医生完全依赖培养结果。所有患者都进行了mNGS检查,但只有培养和mNGS组患者的mNGS结果为临床医生所知。所有患者均开始经验性腹腔内抗菌药物治疗,随后根据临床判断、培养报告和/或mNGS结果调整方案。研究时间从抗感染治疗开始到治疗后3个月。结果包括培养与mNGS的比较性能,基于mNGS的抗菌素耐药性预测准确性以及对治疗决策的临床影响。结果:培养+ mNGS组病原菌检出率显著高于单纯培养组(p = 0.001)。结论:将mNGS纳入诊断工作流程可提高病原体检测效率,加快结果,提高抗菌药物治疗的准确性。这些优势表明,mngs引导的策略可以优化PDAP的临床管理。试验注册:ChiClinicalTrials.gov识别码:CTR2300070995(28/04/2023)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Clinical Value of Metagenomic Next-Generation Sequencing in Early Diagnosis of Peritoneal Dialysis-Associated Peritonitis: A Randomised Controlled Observational Trial.

Clinical Value of Metagenomic Next-Generation Sequencing in Early Diagnosis of Peritoneal Dialysis-Associated Peritonitis: A Randomised Controlled Observational Trial.

Clinical Value of Metagenomic Next-Generation Sequencing in Early Diagnosis of Peritoneal Dialysis-Associated Peritonitis: A Randomised Controlled Observational Trial.

Clinical Value of Metagenomic Next-Generation Sequencing in Early Diagnosis of Peritoneal Dialysis-Associated Peritonitis: A Randomised Controlled Observational Trial.

Aim: While metagenomic next-generation sequencing (mNGS) is a high-throughput diagnostic tool capable of rapidly and accurately identifying pathogenic microorganisms, predicting their antibiotic resistance/susceptibility profiles, its clinical utility in peritoneal dialysis-associated peritonitis (PDAP) remains unvalidated. This study aims to evaluate its ability to enable early pathogen detection and predict antibiotic susceptibility, thereby informing optimised treatment strategies.

Method: A prospective randomised controlled trial was conducted in patients diagnosed with PDAP. Participants were divided into two groups: (1) the culture & mNGS group (n = 78), where both conventional dialysis effluent culture and mNGS were performed, and clinicians had access to mNGS results; and (2) the only culture group (n = 76), where clinicians relied solely on culture results. All patients were examined for mNGS, but only patients in the culture & mNGS group had mNGS results that were known to their clinicians. Empirical intraperitoneal antimicrobial therapy was initiated for all patients, with subsequent regimen adjustments based on clinical judgement, culture reports, and/or mNGS findings. The study duration spanned from the initiation of anti-infective therapy to 3 months post-treatment. Outcomes included the comparative performance of culture versus mNGS, mNGS-based antimicrobial resistance prediction accuracy, and the clinical impact on treatment decisions.

Results: The culture & mNGS group demonstrated a significantly higher pathogen detection rate than the only culture group (p = 0.001). mNGS identified pathogens faster than conventional culture (p < 0.001) and detected polymicrobial infections at a higher rate (p = 0.018). mNGS achieved 88.94% accuracy in predicting antimicrobial resistance. No significant difference was observed between the culture & mNGS group and the only culture group in time to normalisation of dialysis effluent leukocyte counts (p = 0.31).

Conclusion: Integrating mNGS into diagnostic workflows enhances pathogen detection efficiency, accelerates results, and improves the precision of antimicrobial therapy. These advantages suggest that mNGS-guided strategies may optimise clinical management of PDAP.

Trial registration: ChiClinicalTrials.gov identifier: CTR2300070995 (28/04/2023).

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信